The Emergence of In Vivo CAR-Tumor: A Disruptor in Immune Cell Therapy
Interview with Dr. Zhou Guoqing, Inventor of In Vivo CAR-Tumor
Time：
2026-04-09 09:15
Author：
xieyijun
China’s Original Nuclear Power Rises
The "China Storm" in the Radiopharmaceutical Sector
Time：
2026-04-08 09:22
Author：
xieyijun
A+H， Chinese biotech accelerates' dual residency '
Time：
2026-04-06 18:00
Author：
xieyijun
Chinese Innovative Drugs Return to the M&A Arena
The tide will rise again in 2026
Time：
2026-04-05 17:29
Author：
xieyijun
Chinese Innovative Drugs Ignite a Head-to-Head Trial Wave
Time：
2026-04-03 17:59
Author：
xieyijun
Behind Trump’s 100% Tariffs: Unstoppable Rise of China’s Innovative Drugs
US Imposes Tariffs, China Seeks Premiums
Time：
2026-04-03 08:23
Author：
xieyijun
China's innovative drugs going global: from annual prosperity to quarterly explosive growth
Q1 2026 Panorama Review: China Innovative Drug BD
Time：
2026-04-02 08:19
Author：
xieyijun
Wall Street Capital Targets Chinese Biotechs
Renowned VC Firm RA Capital Launches a SPAC
Time：
2026-04-01 08:08
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务